STOCK TITAN

Bausch Health Companies Inc. - $BHC STOCK NEWS

Welcome to our dedicated page for Bausch Health Companies news (Ticker: $BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch Health Companies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch Health Companies's position in the market.

Rhea-AI Summary

Bausch Health, Canada announced additional public drug plan listings for PrUCERIS (budesonide) aerosol foam, expanding access for adults with mild to moderate distal ulcerative colitis. New listings include Alberta, Prince Edward Island, Newfoundland and Labrador, and federal plans for Indigenous people and Veterans. Previously, UCERIS was available in Ontario, Quebec, Saskatchewan, New Brunswick, and Nova Scotia. UCERIS, approved in Canada since September 2023, offers a unique glucocorticosteroid rectal foam for remission induction. Clinical trials showed superior efficacy over placebo in remission and rectal bleeding control at Week 6.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies (NYSE:BHC)(TSX:BHC) and its gastroenterology unit, Salix Pharmaceuticals, will present late-breaking data from a Phase 2 trial of Amiselimod for active ulcerative colitis (UC) at Digestive Disease Week 2024. The presentation, scheduled for May 19, 2024, in Washington D.C., will highlight Amiselimod's potential as an oral treatment for UC remission. The 12-week, double-blind, placebo-controlled study involved 320 patients and showed positive topline results, as announced in December 2023. The abstract, titled "Amiselimod for the treatment of active ulcerative colitis," authored by Stephen B. Hanauer et al., emphasizes Bausch's commitment to innovative UC therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
conferences clinical trial
-
Rhea-AI Summary

Bausch Health (NYSE:BHC, TSX:BHC) announced the results of its 2024 annual meeting of shareholders held on May 14, 2024. All 10 nominated directors were elected with Thomas J. Appio receiving 181,373,219 votes for and 10,918,741 votes withheld. Shareholders approved the compensation of the named executive officers, an amendment to the 2014 Omnibus Incentive Plan, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The final vote results will be reported to the U.S. SEC on Form 8-K and will be available on SEDAR and the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
Rhea-AI Summary

Bausch Health Companies (NYSE:BHC, TSX:BHC) and Salix Pharmaceuticals updated on their litigation with Norwich Pharmaceuticals. Following the US Court of Appeals' April 11, 2024 decision, both companies filed for rehearing. They expect a decision within three months. Additionally, on May 10, 2024, Norwich filed an amendment to their ANDA with the FDA, seeking approval for a generic XIFAXAN® (rifaximin) 550 mg tablets for IBS-D treatment. Bausch has 45 days to file a patent infringement lawsuit, which would delay FDA approval of Norwich's ANDA by up to 30 months or until a court decision.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
Rhea-AI Summary

Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc. (NYSE:BHC), announces Bellamy Young as the spokesperson for Xifaxan, the first FDA approved medication for reducing the risk of OHE recurrence in adults with cirrhosis. Overt Hepatic Encephalopathy is a serious complication of liver cirrhosis, affecting up to 80% of patients. Young aims to raise awareness and share her personal OHE experience to educate patients and caregivers about the management options available through the Xifaxan campaign.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary

Bausch Health announced first quarter 2024 results with revenues of $2.15 billion, up 11%, GAAP net loss of $64 million, and adjusted EBITDA of $665 million, up 13%. The Xifaxan appeal decision is a milestone related to Bausch + Lomb separation. R&D updates include positive data for Amiselimod and progress in other studies. Revenue growth in all segments, with reaffirmed full-year guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.54%
Tags
Rhea-AI Summary
Bausch Health Companies Inc. (BHC) will release its first-quarter 2024 financial results on May 2, 2024, followed by a conference call and webcast to discuss the results and provide a business update. Investors can access all materials on the Investor Relations section of the Bausch Health website. The conference call details include the date, time, and webcast link, with a replay available on the investor relations website. Participants can register for the live Q&A session to receive a PIN before the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals announced that the U.S. Court of Appeals upheld the decision preventing the approval of Norwich Pharmaceuticals' generic version of XIFAXAN until 2029. The Court also invalidated certain patents related to XIFAXAN for treating IBS-D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
-
Rhea-AI Summary
Bausch Health Companies Inc. announces the availability of ARAZLO, a topical prescription treatment for acne vulgaris, through BC PharmaCare in Canada. ARAZLO is the only tazarotene lotion approved by Health Canada for acne treatment in patients 10 years and older. The lotion's PRISMATREX technology helps improve patient tolerability, making it a significant addition to Bausch Health's dermatology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals, Inc. filed a lawsuit against Amneal Pharmaceuticals for seeking approval to market a generic version of XIFAXAN®. The litigation process under the Hatch-Waxman Act has been initiated, triggering a 30-month stay of potential FDA approval for Amneal's ANDA. Bausch Health remains confident in its XIFAXAN® intellectual property and continues to defend it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
none
Bausch Health Companies Inc.

NYSE:BHC

BHC Rankings

BHC Stock Data

2.27B
303.99M
0.91%
79.62%
6.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
QUEBEC

About BHC

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###